Centre for Medicine Use and Safety

In November 2019 we focused on MARC members in the Centre for Medicine Use and Safety (CMUS).

CMUS is located within the Monash Institute of Pharmaceutical Sciences based at the Parkville campus. CMUS conducts multidisciplinary research to optimise the safe and effective use of medicines. This includes research in the community, hospital and residential aged-care settings and their interfaces. CMUS is well positioned given Health Minister Greg Hunt’s recent announcement that medication safety will become Australia’s next national health priority area.


Professor Simon Bell is Director of CMUS and a NHMRC Dementia Leadership Fellow. His research interests primarily relate to investigating and optimising medicines use among older people, particularly psychotropic and analgesic medicines. He has an interest in analyses of administrative pharmacy data. Simon leads the Optimising Geriatric Pharmacotherapy through Pharmacoepidemiology Network (OPPEN) and co-founded the Neurodegenerative Diseases Global Epidemiology Network (NeuroGEN), a new 9-country big data collaboration to generate high quality evidence to improve medication safety.


Dr Johnson George is a Senior Lecturer at CMUS. He conducts multidisciplinary health services research with a focus on chronic respiratory conditions including chronic obstructive pulmonary disease (COPD). He has an interest in smoking cessation services. Johnson led the high profile Review of Airway Dysfunction and Interdisciplinary Community-based care of Adult Long-term Smokers (RADICALS) Randomised Controlled Trial and is currently leading the varenicline and nicotine replacement therapy for smokers admitted to hospitals (VANISH) trial.


Dr Jenni Ilomaki is a Research Fellow with expertise in pharmacoepidemiology. She leads a dynamic and expanding research group focused on analyses of Australian Pharmaceutical Benefits Scheme (PBS) data. She collaborates with a range of government and non-government organisations in Australia and internationally. Jenni is the Chair of the Pharmacoepidemiology Special Interest Group of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT). She is also international convenor of NeuroGEN and Science Lead, Monash Addiction Research Centre (MARC). Jenni is an Executive Editor of the British Journal of Clinical Pharmacology.


Professor Michael Dooley is Director of Pharmacy at Alfred Health and Professor of Clinical Pharmacy at CMUS. His career has focused in the acute healthcare sector and has spanned special clinical roles in oncology through to senior leadership positions within health services. Michael’s research interests include innovative models of clinical pharmacy practice and strategies to improve medication safety in the acute care setting.